CryoPort (NASDAQ:CYRX) Insider Sells $10,969.38 in Stock

Key Points

• Mark Sawicki, an insider at CryoPort, sold 1,341 shares on March 23 at an average price of $8.18 for $10,969.38, leaving him with 102,356 shares (a 1.29% reduction in ownership).
• CryoPort shares were trading up ~3.2% at $8.41; the company reported Q earnings of ($0.21) per share (missing by $0.02) but beat revenue estimates at $45.45 million, with a market cap of ~$419.3M and a P/E of 6.37.
• Analysts are mixed but generally positive: the consensus is a Moderate Buy with a $12.94 target (8 Buys, 1 Hold, 1 Sell), and institutional investors own about 92.9% of the stock after several funds increased positions.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) insider Mark Sawicki sold 1,341 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $8.18, for a total value of $10,969.38. Following the completion of the sale, the insider owned 102,356 shares of the company's stock, valued at approximately $837,272.08. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

CryoPort Trading Up 3.2%

Shares of CYRX traded up $0.26 during midday trading on Wednesday, reaching $8.41. 325,336 shares of the company were exchanged, compared to its average volume of 480,669. CryoPort, Inc. has a 1-year low of $4.63 and a 1-year high of $11.45. The stock has a 50-day moving average price of $8.90 and a 200-day moving average price of $9.32. The company has a market cap of $419.32 million, a price-to-earnings ratio of 6.37 and a beta of 1.69.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $45.45 million for the quarter, compared to analysts' expectations of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. Equities research analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CYRX shares. Needham & Company LLC upped their target price on shares of CryoPort from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of CryoPort in a research note on Monday, December 29th. Finally, Wall Street Zen lowered shares of CryoPort from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $12.94.

Institutional Investors Weigh In On CryoPort

A number of institutional investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. raised its position in shares of CryoPort by 37.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company's stock valued at $14,208,000 after acquiring an additional 408,263 shares in the last quarter. SG Americas Securities LLC boosted its holdings in CryoPort by 663.2% in the third quarter. SG Americas Securities LLC now owns 127,280 shares of the company's stock worth $1,207,000 after purchasing an additional 110,602 shares during the period. Bullseye Asset Management LLC increased its stake in CryoPort by 23.0% during the second quarter. Bullseye Asset Management LLC now owns 260,168 shares of the company's stock valued at $1,941,000 after purchasing an additional 48,605 shares during the last quarter. Thematics Asset Management increased its stake in CryoPort by 12.8% during the second quarter. Thematics Asset Management now owns 1,914,885 shares of the company's stock valued at $14,285,000 after purchasing an additional 216,937 shares during the last quarter. Finally, Mak Capital One LLC acquired a new stake in shares of CryoPort during the third quarter worth $7,756,000. 92.90% of the stock is currently owned by institutional investors.

About CryoPort

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.